A new class of cyclosporin analogues for the treatment of asthma

Bibliography

• HENDERSON DJ, NAYA I, BUNDICK RV, SMITH GM, SCHMIDT JA: Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. Immunology (1991) 73:316–321.
   PubMed Web of Science ®Google Scholar
• FREEMAN DJ: Pharmacology and pharmacokinetics of cyclosporine. Clin. Biochem. (1991) 24:9–14.
   PubMed Web of Science ®Google Scholar
• WATKINS PB: The role of cytochromes P450 in cyclosporine metabolism. Am. Acad. Dermatol (1990) 23:1301-1309; discussion 1309–1311.
   Google Scholar
• KEOWN PA: Optimizing cyclosporine therapy: dose, levels, and monitoring. Transplant Proc. (1988) 20:382–389.
   PubMed Web of Science ®Google Scholar
• REMUZZI G, BERTANI T: Renal vascular and thrombotic effects of cyclosporine. Am.Kidney Dis. (1989) 13:261–272.
   PubMed Web of Science ®Google Scholar
• RUSH DN: Cyclosporine toxicity to organs other than the kidney. Gin. Biochem. (1991) 24:101–105.
   Web of Science ®Google Scholar
• KEOWN PA, STILLER CR, WALLACE AC: Effect of cyclosporine on the kidney. J. Pediam (1987) 111:1029–1033.
   Web of Science ®Google Scholar
• American Hospital Formulary Service: AHFSDrug Information 91 (Edn. 33rd.). American Society of Hospital Pharmacists, Bethesda, MD, USA (1991).
   Google Scholar
• LUKE RG: Mechanism of cyclosporine-induced hypertension. Am. I Hypertens. (1991) 4:468–471.
   PubMed Web of Science ®Google Scholar
• MASON J: The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediam Nephrol (1990) 4:554–574.
   PubMed Web of Science ®Google Scholar
• SCOTT JP, HIGENBOTTAM TW: Adverse reactions and interactions of cyclosporin. Med. Toxicol Adverse Drug Exp. (1988) 3:107–127.
   PubMedGoogle Scholar
• REZNICK VM, LYONS JONES K, DURHAM BL: Changes in facial appearance during cyclosporine treatment. Lancet (1987) 1:1405.
   PubMed Web of Science ®Google Scholar
• LORBER MI: Lessons learned - Future strategies. Clin. Transplant. (1991) 5:505.
   Web of Science ®Google Scholar
• KOPP JB, KLOTMAN PE: Cellular and molecular mechanisms of cyclosporin nephrotoxicity. Jim. Soc. Nephrol (1990) 1:162–179.
   PubMed Web of Science ®Google Scholar
• KON OM, KAY AB: Anti-T cell strategies in asthma. Inflamm. Res. (1999) 48:516–523.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the T-cell strategy inasthma.
   Google Scholar
• ROBINSON DS, HAMID Q, YING S et al.: Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl. J. Med. (1992) 326:298–304.
   PubMed Web of Science ®Google Scholar
• BARNES NC: Specific problems: steroid-induced side effects. In: Manual of Asthma Management. P O'Byrne, N Thomson (Eds), WB Saunders (1995):713–728.
   Google Scholar
• •Review of steroid-resistant asthma.
   Google Scholar
• KAY AB: Role of T cells in asthma. Chem. Immunol (1998) 71:178–191.
   PubMed Web of Science ®Google Scholar
• KON OM, KAY AB: T cells and chronic asthma. Int. Arch. Allergy Immunol (1999) 118:133–135.
   PubMed Web of Science ®Google Scholar
• ELWOOD W, LOT VALL JO, BARNES PJ, CHUNG KF: Effect of dexamethasone and cyclosporin A on allergen-induced airway hyperresponsiveness and inflammatory cell responses in sensitized Brown-Norway rats. Am. Rev Respir. Dis. (1992) 145:1289–1294.
   PubMed Web of Science ®Google Scholar
• UMLAND SP, SHAH H, JAKWAY JP et al.: Effects of cyclosporin A and dinactin on T-cell proliferation, interleukin-5 production, and murine pulmonary inflammation. Am. I Respir. Cell Mol Biol. (1999) 20:481–492.
   PubMed Web of Science ®Google Scholar
• UNDERWOOD SL, MCMILLAN S, REEVES R et al.: Effects of cyclosporin A administered into the airways against antigen-induced airway inflammation and hyperreactivity in the rat. Eur. j Pharmacol (2001) 420:165–173.
   PubMed Web of Science ®Google Scholar
• ••Describes direct application of CsA intothe lungs.
   Google Scholar
• XIE QM, CHEN JQ, SHEN WH, YANG QH, BIAN RL: Effects of cyclosporin A by aerosol on airway hyperresponsiveness and inflammation in guinea pigs. Acta Pharmacol Sin. (2002) 23:243–247.
   PubMed Web of Science ®Google Scholar
• HUANG TJ, EYNOTT P, SALMON M, NICKLIN PL, CHUNG KF: Effect of topical immunomodulators on acute allergic inflammation and bronchial hyperresponsiveness in sensitised rats. Eur: .1 Pharmacol (2002) 437:187–194.
   Google Scholar
• •Good study showing benefit of topical application of CsA to the lung.
   Google Scholar
• ALEXANDER AG, BARNES NC, KAY AB: Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet (1992) 339:324–328.
   PubMed Web of Science ®Google Scholar
• •Pioneering application of CsA in steroid-resistant patients.
   Google Scholar
• LOCK SH, KAY AB, BARNES NC: Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am. I Respir: Crit. Care Med. (1996) 153:509–514.
   PubMed Web of Science ®Google Scholar
• NIZANKOWSKA E, SOJA J, PINIS G et al.: Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur. Respir. J. (1995) 8:1091–1099.
   PubMed Web of Science ®Google Scholar
• FUKUDA T, ASAKAWA J, MOTOJIMA S, MAKINO S: Cyclosporine A reduces T lymphocyte activity and improves airway hyperresponsiveness in corticosteroid-dependent chronic severe asthma. Ann. Allergy Asthma Immunol (1995) 75:65–72.
   PubMed Web of Science ®Google Scholar
• ALEXANDER AG, BARNES NC, KAY AB, CORRIGAN CJ: Clinical response to cyclosporin in chronic severe asthma is associated with reduction in serum soluble interleukin-2 receptor concentrations. Eur: Respir: J. (1995) 8:574–578.
   PubMed Web of Science ®Google Scholar
• •Mechanistic insight into CsA action in chronic severe asthma.
   Google Scholar
• SIHRA BS, KON OM, DURHAM SR, WALKERS, BARNES NC, KAY AB: Effect of cyclosporin A on the allergen-induced late asthmatic reaction. Thorax (1997) 52:447–452.
   PubMed Web of Science ®Google Scholar
• MITRUKA SN, WON A, MCCURRY KR et al.: In the lung aerosol cyclosporine provides a regional concentration advantage over intramuscular cyclosporine. Heart Lung Transplant. (2000) 19:969–975.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of beneficiary exposurereduction by inhaled CsA.
   Google Scholar
• KEENAN RJ, ZEEVI A, IACONO AT et al.: Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics. Surgery (1995) 118:385–391.
   PubMed Web of Science ®Google Scholar
• IACONO AT, KEENAN RJ, DUNCAN SR et al.: Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am. Respir. Grit. Care Med. (1996) 153:1451–1455.
   PubMed Web of Science ®Google Scholar
• ••Pioneering use of aerosolised CsA in lung- transplant patients.
   Google Scholar
• IACONO AT, SMALDONE GC, KEENAN RJ et al.: Dose-related reversal of acute lung rejection by aerosolized cyclosporine. Am. Respir. Crit. Care Med. (1997) 155:1690–1698.
   PubMed Web of Science ®Google Scholar
• GILBERT BE, WILSON SZ, GARCON NM, WYDE PR, KNIGHT V: Characterization and administration of cyclosporine liposomes as a small-particle aerosol. Transplantation (1993) 56:974–977.
   PubMed Web of Science ®Google Scholar
• GILBERT BE, KNIGHT C, ALVAREZ FG et at.: Tolerance of volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol. Am. .1 Respir. Crit. Care Med. (1997) 156:1789–1793.
   Google Scholar
• •Demonstration of clinical feasibility of aerosolised CsA.
   Google Scholar
• ROHATAGI S, CALIC F, HARDING N et al.: Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients. Clio. Pharmacol (2000) 40:1211–1226.
   Google Scholar
• DONATSCH P, MASON J, RICHARDSON BP, RYFFEL B: Toxicologic evaluation of the new cyclosporin derivative, SDZ IMM 125, in a comparative, subchronic toxicity study in rats. Transplant Proc. (1992) 24:39–42.
   PubMed Web of Science ®Google Scholar
• HIESTAND PC, GRABER M, HURTENBACH U et al.: The new cyclosporine derivative, SDZ IMM 125: M vitro and in vivo pharmacologic effects. Transplant Proc. (1992) 24:31–38.
   PubMed Web of Science ®Google Scholar
• WITKAMP L, ZONNEVELD IM, JUNG EG et al.: Efficacy and tolerability of multiple-dose SDZ IMM 125 in patients with severe psoriasis. Br..! Dermatol (1995) 133:95–103.
   PubMed Web of Science ®Google Scholar
• KELLER TH, HERSPERGER R, DELLA CIOPPA G: Macrocyclic immunosuppressants. In: New Drugs for Asthma, Allergy and COPD (Progress M Respiratory Research) (Vol. 31). TT Hansel, PJ Barnes (Eds), Karger (2001):237–240.
   Google Scholar
• •Short review about CsA and FK506 derivatives in asthma.
   Google Scholar
• LAZAROVA T, HAMANN B, CHEN J et al.: Synthesis and biological evaluation of novel cyclosporin a soft drug derivatives with potential usefulness in treating asthma. Annual Meeting of the American Chemical Society Boston, MA, USA (2002).
   Google Scholar
• ECKSTEIN J, LAZAROVA T, HAMANN B et al.: Novel cyclosporine A (CsA) softdrug derivatives for asthma. Annual Meeting of the American Thoracic Society Atlanta, GA, USA (2002).
   Google Scholar
• ECKSTEIN J, LAZAROVA T, HAMANN B et al.: Novel cyclosporine A (CsA) softdrug derivatives for asthma. Clio. Inman. (2002) 103:S80–S81.
   Google Scholar
• BREIMAN A, FAWCETT IW, GHIRARDI ML, MATTOO AK: Plant organelles contain distinct peptidylprolyl cis,trans-isomerases.j. Biol. Chem. (1992) 267:21293–21296.
   PubMed Web of Science ®Google Scholar
• BARNES PJ, CHUNG KF, PAGE CP: Inflammatory mediators of asthma: an update. Pharmacol. Rev (1998) 50:515–596.
   PubMed Web of Science ®Google Scholar
• GIEMBYCZ MA, LINDSAY MA: Pharmacology of the eosinophil. Pharmacol. Rev (1999) 51:213–340.
   PubMed Web of Science ®Google Scholar
• LAZAROVA T, CHEN JS, HAMMANN Bet al.: Synthesis and biological evaluation of novel cyclosporin A analogues: potential soft drugs for the treatment of autoimmune diseases. J. Med. Chem. (2003) 46:674–676.
   Google Scholar